Ardelyx, Inc.

NASDAQ:ARDX

4.64 (USD) • At close December 24, 2024
Bedrijfsnaam Ardelyx, Inc.
Symbool ARDX
Munteenheid USD
Prijs 4.64
Beurswaarde 1,099,002,560
Dividendpercentage 0%
52-weken bereik 4.32 - 10.13
Industrie Biotechnology
Sector Healthcare
CEO Mr. Michael G. Raab
Website https://www.ardelyx.com

An error occurred while fetching data.

Over Ardelyx, Inc.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well

Vergelijkbare Aandelen

DURECT Corporation logo

DURECT Corporation

DRRX

0.97 USD

Axcella Health Inc. logo

Axcella Health Inc.

AXLA

4.58 USD

iCAD, Inc. logo

iCAD, Inc.

ICAD

1.78 USD

Aeglea BioTherapeutics, Inc. logo

Aeglea BioTherapeutics, Inc.

AGLE

12.01 USD

Aptose Biosciences Inc. logo

Aptose Biosciences Inc.

APTO

0.25 USD

LAVA Therapeutics N.V. logo

LAVA Therapeutics N.V.

LVTX

0.975 USD

Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc.

TRVI

4 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)